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Highlights: 
 Effective stroke prevention in atrial fibrillation requires oral anticoagulation. 
 Globally, similar proportions of women and men were prescribed oral 
anticoagulation. 
 The decision to prescribe oral anticoagulation does not seem to be gender-
dependant. 
 Other non-gender risk factors play a predominant role in anticoagulation decision 
making. 
Abstract 
Aims 
Data on gender differences in oral anticoagulation for stroke prevention in patients with 
atrial fibrillation are conflicting, largely limited to regional reports and Vitamin K antagonist 
(VKA) use. We aimed to analyze gender-specific anticoagulant prescription patterns early 
following the introduction of non-VKA oral anticoagulants (NOACs) in a large, global registry 
on atrial fibrillation. 
 
Methods and Results 
Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial 
Fibrillation (GLORIA-AF) is an international registry program involving patients with newly 
diagnosed atrial fibrillation (<3 months from arrhythmia onset). We used data from 15,092 
consecutive patients (median age 71.0 years; women 45.5%) enrolled between 2011 and 
2014. Globally, 79.7% women and 80.2% men were anticoagulated; the absolute between-
gender difference in prevalence of anticoagulant use was −0.5% (95% CI, −1.8%, 0.8%). VKAs 
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were prescribed to 32.8% and 31.9% (NOACs 46.8% and 48.3%) of women and men, 
respectively. No confounder for the association between gender and anticoagulant 
prescription was identified. Between-gender differences in anticoagulant use (lower use in 
women compared with men by decreasing order of magnitude of the difference) were 
found for: CHA2DS2-VASc score=1; CHADS2 score=0; previous bleeding; age <65 years; no 
history of hypertension; myocardial infarction; coronary artery disease; North America 
region; and specialist office setting. 
 
Conclusion 
Globally, the prevalence of anticoagulant use is similar in women and men. The decision to 
prescribe oral anticoagulation seems to depend predominantly upon guideline-related 
differences in stroke risk stratification rather than on gender. 
 
Keywords:  Atrial Fibrillation, Oral Anticoagulation, Gender, GLORIA-AF  
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Introduction 
Atrial fibrillation increases the risk of stroke.1,2 For reasons not entirely clear, 
thromboembolic risk is overall higher in women than in men.3–5 Gender-specific arterial 
structure, alternations in blood flow and endothelial function, increased inflammatory and 
thrombogenic status are examples of the potential reasons for this difference.6,7 
Consequently, female gender has been incorporated into the stroke risk stratification 
scheme, i.e., CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes 
mellitus, stroke/transient ischemic attack [TIA], vascular disease, age 65-74 years, sex 
category [female]).8 The majority of guidelines for atrial fibrillation recommend that oral 
anticoagulation should be considered in patients with  ≥1 non-gender related risk factors for 
stroke (i.e., CHA2DS2-VASc ≥1 in men and CHA2DS2-VASc ≥2 in women).
9–13  
 
Despite these recommendations, published data indicate variability in anticoagulation by 
gender, ranging from a 50% lower uptake in women versus men to more prevalent 
anticoagulation in women.6,14–17 Patients described in these reports were geographically 
clustered and the anticoagulant was largely confined to Vitamin K antagonists (VKAs). Here 
we present findings from Global Registry on Long-Term Oral Antithrombotic Treatment in 
Patients with Atrial Fibrillation (GLORIA-AF), which provides a unique opportunity to assess 
contemporary anticoagulation uptake worldwide.18 The Phase II data allow for analyses of 
early practice patterns following the introduction of non-VKA oral anticoagulants (NOACs). 
Our goal was to assess baseline antithrombotic treatment strategies in women versus men 
and identify potential gender-related gaps in treatment for stroke prevention. 
 
Methods 
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Study Design  
The design of GLORIA-AF has been published.18 In short, GLORIA-AF is a large ongoing, 
prospective registry program enrolling patients with a diagnosis of new onset, non-valvular 
atrial fibrillation at risk for stroke. Inclusion criteria are: adult, newly diagnosed non-valvular 
atrial fibrillation (<3 months prior study enrolment), and ≥1 stroke risk factor in the 
CHA2DS2VASc scale. The main exclusion criteria are mechanical heart valve or valvular 
disease with the need for surgical intervention, prior VKA therapy for any reason for >60 
days, indications other than atrial fibrillation for anticoagulant use, reversible cause of 
arrhythmia and life expectancy <1 year. 
 
Thromboembolic and bleeding risks were assessed based on CHA2DS2-VASc and HAS-BLED 
(hypertension, abnormal renal and liver function, stroke, bleeding, age ≥65 years, drugs or 
alcohol) scales, respectively.8,19 Low-risk of stroke was defined by CHA2DS2-VASc=1 in 
women (men with CHA2DS2-VASc=0 were not recruited); moderate-risk were men with 
CHA2DS2-VASc=1; and high-risk were those with CHA2DS2-VASc score ≥2, irrespective of 
gender. Bleeding risk was defined as low (HAS-BLED score<3) or high (score≥3).19 
 
Data Collection and Timelines 
For collection, storing and assuring safety and confidentiality of data, a validated Electronic 
Data Capture System was employed. To monitor data quality, multiple edit checks, data 
quality reviews and on-site monitoring visits were arranged and local investigators were 
instructed on system functionality and requirements. This analysis is based on cross-
sectional, baseline data of patients enrolled from 2011 through 2014 (Phase II of the 
program, after first NOACs availability). 
Page 5 of 33
 6 
 
Statistical Analysis 
The continuous variables were expressed as median (Q1, Q3), whereas categorical variables 
as frequencies and percentages. To investigate the absolute between-gender difference in 
anticoagulation prescription, both overall and within strata defined by covariates, a 
binomial regression analysis was employed.20  Binomial regression allows direct estimation 
of the difference between proportions of males and females prescribed anticoagulants. The 
first step of the analysis was to screen out potential confounders for gender. The 
change−in−estimate method was applied to verify how much adjusting one covariate can 
change the coefficient (anticoagulant prescription difference) of gender using binomial 
regression. To be considered potential confounders requiring adjustment in subsequent 
multivariable analyses, covariates were required to change the gender coefficient by at least 
10%.  
 
The second step was to investigate the overall gender difference in anticoagulant  
prescription by multivariable binomial regression analysis including gender and all potential 
confounders found, if any, in the first step. The third step was to investigate the gender 
differences within strata defined by covariates of clinical relevance, as outlined in Table S2. 
The multivariable binomial regression analyses were performed, each with 2 risk factors 
(gender and another risk factor) and the interaction term, along with all potential 
confounders found, if any, in the first step, associated with prescription of anticoagulation 
against no anticoagulation.  
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Confidence intervals were based on likelihood ratio. Patients with missing values were 
excluded from the binomial regression analyses. Analyses were performed using SAS 
statistical software version 9.4 (SAS Institute, Inc., Cary, NC, USA).  
 
Results 
Overall, 15,092 consecutive patients (45.5% women) were enrolled (Table 1). Women were 
older, with 45.8% ≥75 years, compared with 33.6% men. The prevalences of hypertension, 
hyperlipidemia, diabetes, previous stroke/TIA, abnormal kidney function, previous bleeding 
episode and cancer were similar in both genders. A quarter of men (24.8%) had coronary 
artery disease and 13.8% prior myocardial infarction, whereas for women the corresponding 
proportions were approximately 50% lower. Paroxysmal atrial fibrillation was more common 
in women (57.2%) than in men (50.1%), as was symptomatic arrhythmia (31.4% versus 
25.5%, respectively).  
 
Based on the CHA2DS2-VASc score, low risk of stroke was observed in 4.8% of women 
(score=1; female with no additional stroke risk factors), and 95.2% were at high risk (score 
≥2). Moderate risk of stroke (score=1) was observed in 21.4% of men and high risk (score ≥2) 
in 78.6% men (Table 2). Bleeding risk was unknown for 10.3% of women (men: 13.2%), low 
for 81.3% of women (men: 77.1%) and high for 8.4% of women (men: 9.7%), as assessed by 
the HAS-BLED score. 
 
Confounders For Gender in the Oral Anticoagulation Prescription 
By the change−in−estimate method, because all covariates caused relatively small changes 
(less than 10%) for the coefficient of gender in the binomial regression, no covariate was 
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identified as a potential confounder that needed adjustment in subsequent analyses (Table 
S1). 
 
Antithrombotic Therapy in Women and Men 
Overall, 79.7% of women and 80.2% men were prescribed anticoagulants (Table 2), the 
absolute between-gender difference (women versus men) in anticoagulant use being −0.5% 
(95% CI, −1.8%, 0.8%) [Table S1]. Anticoagulant choice was similar between genders: 32.8% 
women and 31.9% men were prescribed VKAs (NOACs 46.8 % and 48.3%). Overall, 8.1% of 
women and 7.6% men were given no antithrombotic therapy, while aspirin was prescribed 
to 11.3% of both genders. 
 
Antithrombotic Therapy in Relation to Stroke and Bleeding Risks 
Antithrombotic therapies in relation to thromboembolic risk are presented in Figure 1, Panel 
A. For CHA2DS2-VASc=1, 46.1% of women and 69.8% of men were prescribed anticoagulants, 
whereas the corresponding proportions for CHA2DS2-VASc score ≥2 were 81.4% and 83.0%, 
respectively. Detailed treatment strategies according to stroke risk (as per CHA2DS2-VASc 
score 1-9) are presented in Figure 2, separately for women (Panel A) and men (Panel B).  
 
Of the studied population, 18.3% of women and 17.0% men at low risk of bleeding (HAS-
BLED score of 0-2) were not anticoagulated, whereas the corresponding proportions for 
those at high risk of hemorrhage (HAS-BLED ≥3) were 34.7% and 31.6%, respectively (Figure 
1, Panel B). Aspirin was the most commonly prescribed antithrombotic drug in both women 
(28.3%) and men (27.1%) at high risk of bleeding. 
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Antithrombotic Treatment by Geographic Region  
Apart from evident between-region differences in overall anticoagulant use and choice of 
specific anticoagulant agents, oral anticoagulation by gender was similar within particular 
regions (Figure 3). The exception was noted in North America, where fewer women (75.9%) 
than men (80.4%) were anticoagulated. The corresponding proportions for anticoagulant 
use by females and males in other regions were as follows: 54.4 vs 55.8% in Asia; 89.9 vs 
90.2% in Europe, 86.8 vs 84.1% in Latin America and 88.7 vs 86.3% for Africa/Middle East, 
respectively.   
 
Gender Difference in Anticoagulation Prescription by Covariates  
Gender differences in oral anticoagulant prescription within strata defined by variables of 
clinical relevance and their interaction term associated with prescription of anticoagulation 
against no anticoagulation are presented in Figure 1, Panel C and Table S2. Between-gender 
(women versus men) differences in anticoagulant use were found for (by decreasing order 
of magnitude of the difference): CHA2DS2-VASc score=1; CHADS2 score=0; previous bleeding; 
age <65 years; no history of hypertension; myocardial infarction; coronary artery disease; 
North America region; and specialist office setting. 
 
Discussion 
The principal finding of our study is that globally similar proportions of women (79.7%) and 
men (80.2%) are prescribed oral anticoagulation for stroke prevention in atrial fibrillation. 
Second, oral anticoagulant choice is unaffected by gender (approximately 1/3 and 1/2 are 
prescribed VKAs and NOACs, respectively). Third, when exploring subgroups, the most 
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important difference in anticoagulant use identified between women and men is for 
patients with a CHA2DS2-VASc score of 1 (46.1% of women and 69.8% of men, respectively); 
this difference may be linked to guideline recommendations for atrial fibrillation, hence the 
decision to prescribe anticoagulation is not gender-dependent, but may rely predominately 
upon clinical stroke risk factors.  
 
Although we found no confounders for the association between gender and anticoagulant 
use as well as global anticoagulation was nearly identical amongst women and men, we 
identified several factors of clinical relevance to interact with gender and anticoagulants 
prescription (i.e., thromboembolic risk, previous bleeding, age, geographic region, health 
care setting, comorbid coronary artery disease, myocardial infarction or hypertension). 
 
The largest between-gender difference in anticoagulant use (46.1% and 69.8% for women 
and men, respectively) was found for CHA2DS2-VASc score of 1. This reflects a different 
clinical approach to a score of 1 in both genders, rather than an underuse of anticoagulation 
in women compared with men. On the contrary, women with this score seem over-treated 
with anticoagulants. Indeed, past European guidelines (in effect during enrolment period for 
Phase II of GLORIA-AF, 2011-2014) as well as present guidelines in Europe state that women 
with CHA2DS2-VASc=1 (1 point for female gender only) are at “truly low-risk” for stroke and 
should not be anticoagulated as this brings no benefit but may cause harm.9–11 By contrast, 
anticoagulation should be considered in patients with 1 non-gender related risk factors for 
stroke, that is CHA2DS2-VASc=1 for men and CHA2DS2-VASc=2 for women.
9,10 We observed 
similar proportions of women and men with one non-gender related risk factor being 
anticoagulated (71.9% and 69.1%, respectively). 
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A similar pattern (less anticoagulant use for women than men) was noted for those aged 
<65 years with no history of hypertension, which seems to reflect treatment strategy for low 
risk patients. We observed no between-gender differences for patients ≥65 years of age or 
with comorbid hypertension. Indeed, on the other side of the stroke risk continuum (high-
risk cohort), as defined by the CHA2DS2-VASc ≥2 (regardless of gender), we observed a 
similar anticoagulation by women and men, at 81.4% and 83.0%, respectively. Nonetheless, 
we found that fewer women than men were anticoagulated if they had a previous bleeding 
event, even though no major between-gender differences were noted with regard to 
bleeding risk, as per HAS-BLED scheme. The reasons for this disparity in anticoagulation 
patterns between men and women are not fully understood, but perhaps may reflect a 
differently perceived (higher in women) risk of bleeding complications in relation to gender. 
Importantly, the net clinical benefit of anticoagulation, when balancing stroke risk reduction 
versus increased risk of bleeding, is positive and even greater in patients at increased risk of 
bleeding.21,22 
 
Regional disparities in anticoagulant use by gender may result from various guideline 
recommendations issued by different societies, largely due to different thresholds for 
anticoagulation initiation.23,24 We found that fewer women than men were anticoagulated 
in North America. Our findings are consistent with recent report of the PINNACLE Registry, 
which found that in North America women are less likely to be anticoagulated.25 Unlike 
European guidelines, the American recommendations offer OAC, aspirin or no stroke 
prophylaxis to patients with CHA2DS2-VASc=1 (regardless of gender), whereas 
anticoagulation is recommended for those with the score ≥2.11,26 By considering female 
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gender as a risk factor for those with CHA2DS2-VASc=1, the American guidelines (in contrast 
to European guidelines) could potentially be recommending anticoagulation for women who 
may be at truly low risk for stroke (thus, potential drug overuse), whereas anticoagulants 
may be underused in men at moderate risk of stroke.24,27,28 Although the difference in 
anticoagulation rates amongst women versus men in North America is modest, patients 
with one risk factor for stroke constitute only the minority of atrial fibrillation population, 
for example only 13.9% in the present analysis (and taking into account the fact that men 
with CHA2DS2-VASc=0 were not recruited by GLORIA-AF). Importantly, though 1-year stroke 
rates in untreated patients with only 1 risk factor for stroke (beyond gender) vary amongst 
studies, the majority of reports show evident clinical benefit of anticoagulation versus no 
anticoagulation.24,27–30 The same reports show also no benefit of anticoagulation in patients 
with no stroke risk factors, that is men with CHA2DS2-VASc=0 and women with CHA2DS2-
VASc=1 (one point for female gender only). 
 
In Canada, female gender is not perceived as a stroke risk factor and anticoagulation is 
recommended for patients with CHADS2 ≥1 (Congestive Heart Failure, Hypertension, 
Age≥75, Diabetes, Stroke/TIA).31 We observed no difference in anticoagulant use by gender 
for CHADS2 ≥1, but fewer women than men were anticoagulated if CHADS2 score was 0. In 
contrast to CHA2DS2-VASc scoring system, employment of CHADS2 scheme may 
underestimate the risk of stroke in patients categorized as low risk (score=0).32  Indeed, in 
Canada, a woman age <65 years with vascular disease is not recommended anticoagulation 
(CHADS2=0), whereas in Europe anticoagulation is considered/indicated (CHA2DS2-VASc=2) 
for such women.9–12 Importantly, women versus men with vascular disease (i.e. coronary 
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artery disease and prior myocardial infarction) in the present analysis were less likely to be 
anticoagulated. 
 
A recent report from 3 nationwide registries suggests that female gender is a “stroke risk 
modifier” rather than a “stroke risk factor” and although stroke risk may be higher in 
women versus men it seems that “female gender” may be safely omitted in decision making 
on oral anticoagulation prescription.33 Thus, use of a CHA2DS2-VA score (i.e. excluding 
gender criterion) may be considered.  
 
Limitations 
Per study protocol, GLORIA-AF recruited patients with CHA2DS2-VASc score ≥1. Thus, no data 
on males with score zero (low-risk of stroke) were available. Our analyses are based on the 
prescription of baseline anticoagulation in relation to gender, and thus we could assess 
neither quality of anticoagulation nor changes in practice patterns over time. Only patients 
with new onset atrial fibrillation (not all-comers) were recruited. Both patients and 
physicians knew they were participants of a registry program and patients could join the 
study only after signing an informed consent. This might have led to higher overall 
anticoagulation rates compared with general population. 
In order to analyze many clinically important factors affecting decision making on 
anticoagulation prescription, we have performed a log-binomial analysis of anticoagulant 
use against no anticoagulant use, instead of analyzing the use of each of the anticoagulants 
separately. Also, we did not analyze the associations between anticoagulant use and 
concomitant dual antiplatelet therapy use by gender. A detailed analysis of various 
combinations of antiplatelet therapy use ± anticoagulant use that may have varying 
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durations of use is beyond the scope of the current analysis that focuses on gender 
differences. 
We used a 10% absolute change in the coefficient of gender as a cut-off for identification of 
confounders of the association between gender and anticoagulant use. More typically, a 
10% relative change is used. We opted for an absolute cut-off because the effect of gender 
on anticoagulant use seems nearly null. The results would have been unchanged for any 
absolute change threshold above 2.3% (Table S1). With the threshold 2.3% (or any above 
1.1%), the retained model would have adjusted for CHA2DS2−VASc score and the resulting 
absolute difference in anticoagulation between women and men would have shifted from -
0.5% (95% CI −1.8, 0.8) to -2.8% (−4.0,−1.5) (Table S1), which would still support our 
principal finding that the oral anticoagulant use is globally similar between women and men. 
In addition, a model estimating the effect of gender when adjusting for all other factors has 
been reported;34 the effect of gender on anticoagulation was not affected by the 
adjustments (relative risk of anticoagulant prescription for females compared with males: 
0.99 unadjusted vs. 0.99 adjusted for all other factors). We have therefore no reason to 
suspect that our results were sensitive to this choice. 
A few variables had non-negligible proportions of missing values. For example, creatinine 
clearance had 21% missing, HAS-BLED score had 12% missing, and alcohol abuse had 8% 
missing. Multiple imputation to deal with missing values was not planned in the phase II 
analyses, which are mostly descriptive, but this will be considered for phase III.  
 
Conclusion 
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Globally, the prevalence of anticoagulant use is similar in women and men. The decision to 
prescribe oral anticoagulation seems to depend predominantly upon guideline-related 
differences in stroke risk stratification rather than on gender. 
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Legends 
Figure 1 Gender Differences in Antithrombotic Therapy Prescription by Stroke (Panel A) and 
Bleeding Risk (Panel B) and Covariates (Panel C) 
 
ASA – aspirin;  VKA – Vitamin K antagonists; Other – antiplatelets other than aspirin and combination of 
antithrombotic agents; HAS-BLED – missing values = 706 (10.3%) in women and 1083 (13.2%) in men  
 
Figure 2 Antithrombotic Treatment in Relation to Stroke Risk in Females (Panel A) and Males 
(Panel B) 
ASA – aspirin;  OAC – oral anticoagulant; Other – antiplatelets other than aspirin and combination of 
antithrombotic agents; N/A – not applicable in men 
 
Figure 3  Antithrombotic Treatment by Gender and Region 
ASA – aspirin;  NOAC - non-Vitamin K antagonist oral anticoagulants; VKA – Vitamin K antagonists; Other – 
antiplatelets other than aspirin and combination of antithrombotic agents 
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Table 1  Baseline Characteristics  
N (%) or median [Q1, Q3] 
All 
n=15,092 
(100%) 
Women 
n=6872 
(45.5%) 
Men 
n= 8220 
(54.5%) 
Patient characteristics    
Age, years (median [Q1, Q3]) 71.0 (64.0, 78.0) 73.0 (66.0, 80.0) 70.0 (62.0, 77.0) 
<65 years 4064 (26.9) 1464 (21.3) 2600 (31.6) 
65-74 years 5121 (33.9) 2261 (32.9) 2860 (34.8) 
≥75 years 5907 (39.1) 3147 (45.8) 2760 (33.6) 
Current-smoker 1428 (9.5) 320 (4.7) 1108 (13.5) 
Past smoker 4376 (29.0) 1127 (16.4) 3249 (39.5) 
Creatinine clearance [ml/min] 
(median [Q1, Q3]) 
73.5 (55.3, 97.0) 66.8 (50.4, 87.9) 80.4 (60.6, 103.9) 
Medical history    
Hypertension 11255 (74.6) 5177 (75.3) 6078 (73.9) 
Hyperlipidemia 6026 (39.9) 2671 (38.9) 3355 (40.8) 
Diabetes mellitus 3487 (23.1) 1472 (21.4) 2015 (24.5) 
Previous stroke/TIA 2147 (14.2) 1008 (14.7) 1220 (14.8) 
Congestive heart failure 3647 (24.2) 1419 (20.6) 2228 (27.1) 
      Ejection fraction <40%a 1388 (38.1) 370 (26.1) 1018 (45.7) 
Coronary artery disease 3068 (20.3) 1029 (15.0) 2039 (24.8) 
Myocardial infarction 1600 (10.6) 464 (6.8) 1136 (13.8) 
Peripheral artery disease 475 (3.1) 130 (1.9) 345 (4.2) 
Chronic gastrointestinal 
diseases 
1976 (13.1) 960 (14.0) 1016 (12.4) 
Abnormal kidney functionb 241 (1.6) 80 (1.2) 161 (2.0) 
Previous bleeding event 842 (5.6) 382 (5.6) 460 (5.6) 
Alcohol abuse, ≥8 units/week 996 (6.6) 158 (2.3) 838 (10.2) 
Cancer 1401 (9.3) 619 (9.0) 782 (9.5) 
Type of AF    
Paroxysmal 8052 (53.4) 3931 (57.2) 4121 (50.1) 
Persistent 5362 (35.5) 2224 (32.4) 3138 (38.2) 
Permanent 1678 (11.1) 717 (10.4) 961 (11.7) 
Categorization of AF    
Symptomatic 4263 (28.2) 2157 (31.4) 2106 (25.6) 
Minimally Symptomatic 6004 (39.8) 2896 (42.1) 3108 (37.8) 
Asymptomatic 4825 (32.0) 1819 (26.5) 3006 (36.6) 
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Interventions in AF    
AF cardioversion 2431 (16.1) 1084 (15.8) 1347 (16.4) 
AF ablation 161 (1.1) 61 (0.9) 100 (1.2) 
Health-care setting    
GP/primary care 968 (6.4) 451 (6.6) 517 (6.3) 
Specialist office 4567 (30.3) 2034 (29.6) 2533 (30.8) 
Community hospital 3969 (26.3) 1870 (27.2) 2099 (25.6) 
University hospital 5081 (33.7) 2286 (33.3) 2795 (34.0) 
Outpatient health care center 239 (1.6) 113 (1.6) 126 (1.5) 
Anticoagulation clinic 142 (0.9) 60 (0.9) 82 (1.0) 
Other 126 (0.8) 58 (0.8) 68 (0.8) 
Region    
Region 1 – Asia 3071 (20.3) 1337 (43.5) 1734 (56.5) 
Region 2 – Europe 7108 (47.1) 3317 (46.7) 3791 (53.3) 
Region 3 – North America 3403 (22.5) 1524 (44.8) 1879 (55.2) 
Region 4 – Latin America 913 (6.0) 410 (44.9) 503 (55.1) 
Region 5 – Africa/Middle East 597 (4.0) 284 (47.6) 313 (52.4) 
 
AF = atrial fibrillation; GP = general practitioner; SD = standard deviation; TIA = transient ischemic attack 
a
For patients with congestive heart failure 
b
Defined as the presence of chronic dialysis or renal transplantation or serum creatinine ≥200 μmol/L  
Unknown/missing values: 1188 for alcohol abuse, 565 for smoking status, 440 for hyperlipidemia, 243 for 
abnormal kidney function, 15 for physician specialty, 941 for medical reimbursement, 2 for TIA/stroke, 411 for 
coronary artery disease, 9 for myocardial infarction, 149 for congestive heart failure, 36 for hypertension, 133 
for peripheral artery disease, 117 for cancer, 172 for chronic gastrointestinal diseases, 276 for prior bleeding, 
220 for AF cardioversion, 145 for AF ablation, 3221 missing for creatinine clearance. 
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Table 2  Thromboembolic/Bleeding Risk and Antithrombotic Therapy by Gender 
N (%) or median [Q1, Q3] 
All 
n=15,092 
(100%) 
Women 
n=6872 
(45.5%) 
Men 
n= 8220 
(54.5%) 
CHADS2 (median [Q1, Q3]) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (1.0, 2.0) 
Low Risk (score 0) 1221 (8.1) 730 (10.6) 491 (6.0) 
Moderate Risk (score 1) 5150 (34.1) 2086 (30.4) 3064 (37.3) 
High Risk (score≥2) 8719 (57.8) 4055 (59.0) 4664 (56.7) 
Missing data 2 (0.0) 1 (0.0) 1 (0.0) 
CHA2DS2-VASc (median [Q1, Q3]) 3.0 (2.0, 4.0) 4.0 (3.0, 5.0) 3.0 (2.0, 4.0) 
Low Risk (score 1 in women) 332 (2.2) 332 (4.8) - 
Moderate Risk (score 1 in men) 1761 (11.7) - 1761 (21.4) 
High Risk (score≥2) 12999 (86.1) 6540 (95.2) 6459 (78.6) 
HAS-BLED (median [Q1, Q3]) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0) 
Low Risk (score 0-2) 11927 (79.0) 5590 (81.3) 6337 (77.1) 
High Risk (score≥3) 1376 (9.1) 576 (8.4) 800 (9.7) 
Missing Data 1789 (11.9) 706 (10.3) 1083 (13.2) 
Antithrombotic Therapy    
None 1182 (7.8) 558 (8.1) 624 (7.6) 
ASA  1706 (11.3) 774 (11.3) 932 (11.3) 
VKA 4878 (32.3) 2255 (32.8) 2623 (31.9) 
NOAC 7187 (47.6) 3219 (46.8) 3968 (48.3) 
Dabigatran 4767 (31.6) 2122 (30.9) 2645 (32.2) 
Rivaroxaban 1726 (11.4) 761 (11.1) 965 (11.7) 
Apixaban 694 (4.6) 336 (4.9) 358 (4.4) 
Other 139 (0.9) 66 (0.9)  73 (0.9)  
Overall oral anticoagulation 12065 (79.9) 5474 (79.7)  6591 (80.2)  
 
ASA = aspirin; NOAC = non-Vitamin K antagonist oral anticoagulants; VKA = Vitamin K antagonists; Other = 
antiplatelets other than aspirin and combination of anticoagulant agents;  SD = standard deviation 
Unknown/missing values:  2 for CHADS2 score class, 1786 for HAS-BLED risk score class. 
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Table S1  Binomial Regression Analysis to Select Confounding Variables For Gender Analysis 
Using Change−in−Estimate Method with 0.10 cut-off For Absolute Change − Dependent 
Variable in the Models is the Proportion of OAC Prescription (VKA, NOAC) 
 
 
 
Gender models 
       Gender difference of  
       OAC prescription  
        coefficient of sex 
        % (95% CI) 
  Absolute change  
  in estimate of  
  sex coefficient 
No adjustment for other variable       −0.5 (−1.8, 0.8)       0.0 
Adjustment of Age −1.2 (−2.4, 0.1) 0.7 
Adjustment of Type of AF   0.2 (−1.0, 1.4) 0.7 
Adjustment of Categorization of AF −0.4 (−1.7, 0.8) 0.1 
Adjustment of AF cardioversion −0.5 (−1.8, 0.8) 0.0 
Adjustment of Hypertension −0.3 (−1.6, 0.9) 0.2 
Adjustment of Diabetes mellitus −0.4 (−1.7, 0.8) 0.1 
Adjustment of Previous stroke/TIA −0.5 (−1.7, 0.8) 0.0 
Adjustment of Congestive heart failure −0.5 (−1.8, 0.8) 0.0 
Adjustment of Coronary artery disease −1.0 (−2.3, 0.3) 0.5 
Adjustment of Myocardial infarction −0.7 (−2.0, 6.0) 0.2 
Adjustment of Peripheral artery disease −0.4 (−1.7, 0.9) 0.1 
Adjustment of Previous bleeding events −0.4 (−1.7, 0.9) 0.1 
Adjustment of Creatinine clearance <60ml/min −0.2 (−1.6, 1.3) 0.3 
Adjustment of Alcohol abuse −1.0 (−2.4, 0.3) 0.5 
Adjustment of Cancer −0.5 (−1.7, 0.8) 0.0 
Adjustment of Chronic gastrointestinal diseases −0.4 (−1.7, 0.8) 0.1 
Adjustment of No coverage for medications −0.9 (−2.2, 0.4) 0.4 
Adjustment of CHADS2   0.1 (−1.1, 1.4) 0.6 
Adjustment of CHA2DS2−VASc  −2.8 (−4.0,−1.5) 2.3 
Adjustment of HAS−BLED  −1.6 (−3.0,−0.3) 1.1 
Adjustment of Region −0.7 (−1.9, 0.4) 0.2 
Adjustment of Type of site −0.5 (−1.8, 0.7) 0.0 
Adjustment of Physician specialty −0.6 (−1.9, 0.7) 0.1 
 
For abbreviations and unknown/missing values please refer to footnotes of Table 1-2; 12 patients who were 
prescribed a combination of OACs and patients with unknown/missing values were excluded from the binomial 
regression analyses.                 
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Table S2 Multivariable Analysis For Gender Differences by Covariates – Binomial Regression 
Analysis with 2 Risk Factors (Gender and Another Risk Factor) and Their Interaction Term 
Associated with Prescription of OAC against No OAC 
 
Strata defined  
by covariates 
      Men 
Number of 
pts 
(on 
OAC/total)  
    Women 
Number of 
pts 
(on 
OAC/total)  
Gender difference of 
OAC prescription  
(Reference = Male;  
%, 95% CI) 
Age category    
<65 years 1974/2599  1013/1462  −6.7 (−9.5,−3.8) 
65-74 years 2332/2859 1837/2259 −0.2 (−2.4,  1.9) 
≥75 years 2285/2757  2624/3144    0.6 (−1.3,  2.5) 
Type of AF    
Paroxysmal 3085/4117 2952/3927   0.2 (−1.7,  2.1) 
Persistent 2626/3137 1864/2221   0.2 (−1.8,  2.2) 
Permanent 880/961 658/717   0.2 (−2.5,  2.9) 
Categorization of AF    
Symptomatic 1704/2106 1784/2155   1.9 (−0.4,  4.2) 
Minimally 
Symptomatic 
2455/3106 2244/2894 −1.5 (−3.6,  0.6) 
Asymptomatic  2432/3003 1446/1816 −1.4 (−3.7,  1.0) 
AF cardioversion    
No 5379/6738 4526/5695 −0.4 (−1.8,  1.1) 
Yes 1109/1347 876/1080 −1.2 (−4.3,  1.9) 
Hypertension    
No  1648/2118 1197/1682 −6.6 (−9.4,−3.8) 
Yes 4927/6073 4265/5171   1.3 (−0.1,  2.8) 
Diabetes mellitus    
No  4909/6203 4270/5394   0.0 (−1.5,  1.5) 
Yes 1682/2012 1204/1471 −1.7 (−4.3,  0.8) 
Previous stroke/TIA    
No  5612/7035 4675/5898 −0.5 (−1.9,  0.9) 
Yes 978/1179 799/966 −0.2 (−3.4,  3.0) 
Congestive heart failure    
No  4697/5898 4281/5388 −0.2 (−1.7,  1.3) 
Yes 1830/2228 1142/1417 −1.5 (−4.1,  1.1) 
Coronary artery disease    
No  4835/5964 4565/5640 −0.1 (−1.6,  1.3) 
Yes 1575/2038 736/1027 −5.6 (−8.9,−2.3) 
Myocardial infarction    
No  5693/7072 5137/6401 −0.2 (−1.6,  1.1) 
Yes 892/1135 336/463 −6.0 (−10.7,−1.3) 
Peripheral artery disease    
No  6224/7776 5343/6697 −0.3 (−1.6,  1.1) 
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Yes 284/344 101/130 −4.9 (−13.1, 3.3) 
Previous bleeding events    
No  6074/7588 5103/6375 −0.0 (−1.3,  1.3) 
Yes 368/460 278/382  −7.2 (−13.0,−1.5) 
Creatinine clearance <60ml/min    
No  3917/4849 2627/3312 −1.5 (−3.2,  0.3) 
Yes 1210/1549 1737/2149   2.7 (  0.1,  5.4) 
Alcohol abuse    
No  5343/6639 4973/6259 −1.0 (−2.4,  0.4) 
Yes 683/838 127/157 −0.6 (−7.3,  6.1) 
Cancer    
No  5882/7369 4915/6197 −0.5 (−1.9,  0.9) 
Yes 648/781 512/617   0.0 (−4.0,  4.0) 
Chronic gastrointestinal diseases    
No  5690/7106 4640/5828 −0.5 (−1.8,  0.9) 
Yes 814/1016 765/958 −0.3 (−3.8,  3.3) 
No reimbursement for medications    
No  5758/7123 4746/5940 −0.9 (−2.3,  0.4) 
Yes 443/591 363/485 −0.1 (−5.3,  5.1) 
CHADS2 score    
Score 0 348/491 442/729      −10.2 (−15.6,−4.9) 
Score 1 2339/3064 1637/2085   2.2 (−0.1,  4.5) 
Score ≥2 3903/4659 3395/4050   0.1 (−1.5,  1.6) 
CHA2DS2-VASc score    
Score 1  1230/1761 153/332      −23.8 (−29.5,−18.0) 
Score ≥2 5361/6454 5321/6533 −1.6 (−2.9,−0.3) 
HAS-BLED score    
Score 0-2 5227/6332 4528/5586 −1.5 (−2.9,−0.1) 
Score ≥3 520/800 353/576 −3.7 (−8.9,  1.5) 
Region    
Region 1 - Asia 967/1734 727/1337 −1.4 (−4.9,  2.2) 
Region 2 - Europe 3421/3790 2983/3313 −0.2 (−1.6,  1.2)  
Region 3 - North 
America 
1510/1875 1156/1521 −4.5 (−7.3,−1.7)  
Region 4 - Latin 
America 
423/503 356/410   2.7 (−1.8,  7.3) 
Region 5 - 
Africa/Middle East 
270/313 252/284   2.5 (−2.8,  7.8) 
Type of site    
Primary care 383/517 327/451 −1.6 (−7.2,  4.0) 
Specialist office 2050/2530 1584/2032 −3.1 (−5.4,−0.7) 
Community hospital 1804/2099 1607/1867   0.1 (−2.0,  2.3) 
University hospital 2106/2793 1744/2284   1.0 (−1.4,  3.3) 
Outpatient health 
care center 
112/126 102/113   1.4 (−6.4,  9.1) 
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Anticoagulation 
clinic 
74/82 56/60   3.1 (−5.9, 12.1) 
Other 62/68 54/58   1.9 (−7.5, 11.3) 
Physician specialty    
GP/Geriatrician 148/198 122/161   1.0 (−7.9,  10.0) 
Cardiologist 6066/7576 4989/6275 −0.6 (−1.9,  0.8) 
Neurologist 71/77 57/70      −10.8 (−21.7,  0.1) 
Internist 137/174 119/148   1.7 (−7.2,  10.5) 
Other 160/181 181/205 −0.1 (−6.5,  6.3) 
 
For abbreviations and unknown/missing values please refer to footnotes of Table 1-2; 12 patients who were 
prescribed a combination of OACs and patients with unknown/missing values were excluded from the binomial 
regression analyses. 
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Page 32 of 33
 33 
 
Figure 3.tif 
Page 33 of 33
